Therapeutic epigenome editing creates an unusual temporal problem: the molecular editor may be present only briefly, whereas the regulatory state established during that exposure can persist long after the initiating intervention has disappeared. Durable repression after transient delivery has now been demonstrated in several experimental settings, yet persistence is not an intrinsic consequence of depositing an epigenetic mark. Regulatory outcomes vary with locus architecture, chromatin context, effector design, cell state, proliferation, and the molecular processes that maintain or erase the installed state. This article develops a mechanistic account of post-editing persistence that distinguishes the duration of editor exposure from the lifetime of the resulting regulatory state. It argues that durable gene regulation should be understood as a trajectory emerging after editor withdrawal, governed by the balance between local chromatin reinforcement, replication-coupled inheritance, transcriptional feedback, competing regulatory inputs, and active or passive erasure. The account further separates persistence from irreversibility: a regulatory state may remain stable for prolonged periods while retaining molecular routes to reactivation. This distinction has consequences for therapeutic design, because insufficient persistence can eliminate benefit whereas excessive or poorly reversible persistence may create a different safety problem. A mechanistically credible evaluation of therapeutic epigenome editing therefore requires longitudinal evidence after verified editor clearance, measurements that connect chromatin state with transcriptional function, and perturbations capable of discriminating self-maintenance from continued exposure or other explanations.
